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One of the quiet revolutions occurring in the pharmaceuti-
cal industry has been the transformation of prescription
drugs to over-the-counter (OTC) medications. I remember
when the H2 blockers were first introduced OTC; I was
amazed that such a class of drugs could make that transfor-
mation. Many of the NSAIDS followed suit, and now it
seems that many others are poised to do the same thing.
The potential for long-term pharmaceutical company profit
is staggering.
A few years ago, while talking to pharmaceutical com-
pany leaders, I was informed that they had made corporate
decisions to spend more and more of their advertising
budget on ads that went directly to the consumer, including
television, magazines, etc. At the time, I was concerned
about the decrease in advertising revenue for JACC, which,
by the way, has occurred. Although companies still advertise
new drugs in the medical journals, they have shifted their
advertising for established drugs to the general public. The
appearance on television of noted people such as Bob Dole
and Dan Reeves has enhanced the anecdotal power of this
advertising. The closing statement of these ads, which used
to say, “See your doctor,” may soon say, “Available in your
neighborhood drugstore.”
Current examples of this transformation are the statin
drugs. A recent FDA hearing heard testimony pro and con
about proposed OTC drugs in general, and especially the
statins. There are interesting arguments for making the
statins available OTC. They have been extremely beneficial
drugs for both primary and secondary prevention of coro-
nary artery disease. They have reduced morbidity and
mortality while, at the same time, they have been remark-
ably free from side effects and serious adverse reactions. The
public is very interested in taking charge of their own health
these days. The wave of “dot coms” that provide medical
information and advice urges individuals to take charge of
their own well-being. The billions spent each year in this
country on vitamins, minerals, herbs, and other alternative
therapies attest to the almost insatiable desire of many
Americans to prevent disease and to treat themselves. Of
course, the statins would be offered in low dose (equivalent
to 10 mg lovastatin), as are all OTC medications, but this
still might help in lowering LDL cholesterol. Instructions
would be included about lifestyle changes (especially diet
and exercise) and the need for lab measurements and
physician input into the process.
Arguments against OTC use can also be persuasive.
Although they are remarkably side effect–free, the statins do
have an occasional downside, including liver and skeletal
muscle toxicity. These can generally be discovered only by
blood tests, and it is unclear how many patients will actually
get their blood drawn. Previous OTC medicines (e.g., H2
blockers and NSAIDS) frequently had measurable symp-
tomatic end points that allowed OTC users to judge dosing
and efficacy, making them easier to use appropriately. No
such clinical feedback is available with the statins, which are
meant to prevent disease in asymptomatic individuals. A
similar FDA review is underway to consider providing
certain antihypertensive drugs OTC to control blood pres-
sure, another asymptomatic syndrome. The side effect
profile of certain antihypertensive agents may make this
decision more problematic. Will patients buy blood-
pressure measuring devices, or will they get their blood
pressure checked regularly in their local drugstore or mall?
Will patients regularly get their blood measured (up to a
year) for liver enzymes and lipids if they are on statin drugs?
Another issue with OTC statins is whether or not some
individuals will be falsely reassured by being on a statin
drug, when they really need far higher doses. An equivalent
dose of 10 mg lovastatin pales next to doses of 80 mg, which
have been used in some clinical trials. If patients elected to
use multiple 10 mg doses, they might pay much more than
the equivalent prescription dose because some manufactur-
ers have flat pricing across all their prescription doses.
Furthermore, depending on their insurance coverage, con-
sumers may get prescription drugs for a copayment that is
much less than the price of OTC drugs, for which they must
pay out of their pockets. This may result in consumers
paying too much for ineffective dose levels. This is exactly
the circumstance decried for the natural herbs and supple-
ments—too little “bang for the buck.” Although OTC
instructions would include advice about the necessity of
physician monitoring, this is no different from current
practice, wherein patients receive prescriptions from their
physicians and are followed in the office. Our current
practice seems to avoid the pitfalls outlined above for OTC
medications.
Our primary responsibility as physicians is to put our
patients’ health and well-being above all other consider-
ations. Protection of the patient is implicit in that respon-
sibility, as is optimum care. At the present time, I believe
that a caring and informed physician can provide an edge in
optimum care and safety that even the best intentioned and
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well-informed patient cannot match. It seems self-evident
that not all drugs should reach OTC status. The real
question, therefore, is where to draw the line. That is the
current FDA challenge. Hopefully, physicians and medical
societies will offer appropriate input into this quiet revolu-
tion. There are no black or white answers, but the gray zone
has the capacity to dramatically transform medical care
forever. We have the opportunity to make sure that the
risk/benefit ratio markedly favors patient well-being.
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